In the included patients ( n = @ otelixizumab , n = @ placebo ) , - cell function was assessed as area under the curve ( AUC ) C-peptide release during a hyperglycemic glucose clamp at baseline ( median duration of insulin treatment : @ days ) and every @ months until @ months after randomization .